{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:23:01Z","timestamp":1774437781365,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1038\/ki.2013.289","type":"journal-article","created":{"date-parts":[[2013,7,31]],"date-time":"2013-07-31T12:39:11Z","timestamp":1375274351000},"page":"191-197","source":"Crossref","is-referenced-by-count":56,"title":["AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients"],"prefix":"10.1016","volume":"85","author":[{"given":"Kevin J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Pickthorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saling","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey A.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Vick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Mount","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.289_bb0010","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.289_bb0015","series-title":"USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States","author":"US Renal Data System","year":"2009"},{"key":"10.1038\/ki.2013.289_bb0020","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.289_bb0025","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.289_bb0030","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0272-6386(97)90484-4","article-title":"Effects of excess PTH on nonclassical target organs","volume":"30","author":"Bro","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.289_bb0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00000441-200008000-00008","article-title":"Management of secondary hyperparathyroidism: the gap between diagnosis and treatment. The Renal Osteodystrophy Multicenter Enquiry","volume":"320","author":"Diaz-Corte","year":"2000","journal-title":"Am J Med Sci"},{"issue":"Suppl 3","key":"10.1038\/ki.2013.289_bb0040","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1177\/089686080102103S43","article-title":"Current issues in the management of secondary hyperparathyroidism and bone disease","volume":"21","author":"Moe","year":"2001","journal-title":"Perit Dial Int"},{"key":"10.1038\/ki.2013.289_bb0045","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s004670050183","article-title":"The management of renal osteodystrophy","volume":"10","author":"Salusky","year":"1996","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2013.289_bb0050","first-page":"F1","article-title":"Parathyroid hormone metabolism and its potential as a uremic toxin","volume":"239","author":"Slatopolsky","year":"1980","journal-title":"Am J Physiol"},{"key":"10.1038\/ki.2013.289_bb0055","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.289_bb0060","series-title":"Kidney Int Suppl","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009"},{"issue":"Suppl 1","key":"10.1038\/ki.2013.289_bb0065","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1111\/j.1440-1797.2006.00508.x","article-title":"The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone","volume":"11","author":"Elder","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"Suppl 1","key":"10.1038\/ki.2013.289_bb0070","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1111\/j.1744-9987.2007.00516.x","article-title":"Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism","volume":"11","author":"Kazama","year":"2007","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2013.289_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1053\/j.ajkd.2010.02.340","article-title":"KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)","volume":"55","author":"Uhlig","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.289_bb0080","doi-asserted-by":"crossref","first-page":"F1192","DOI":"10.1152\/ajprenal.00360.2009","article-title":"Deletion of the vitamin D receptor specifically in the parathyroid demonstrates a limited role for the receptor in parathyroid physiology","volume":"297","author":"Meir","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"Suppl 1","key":"10.1038\/ki.2013.289_bb0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/ndt\/13.suppl_1.40","article-title":"Regulation of the parathyroid hormone gene by calcium, phosphate and 1,25-dihydroxyvitamin D","volume":"13","author":"Silver","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.289_bb0090","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"key":"10.1038\/ki.2013.289_bb0095","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2013.289_bb0100","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.289_bb0105","unstructured":"Walter S, Baruch A, Alexander S et al. AMG 416, a novel peptide agonist of the calcium-sensing receptor, is active in rodent models of uremia. Submitted."},{"key":"10.1038\/ki.2013.289_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.113.204834","article-title":"Pharmacology of AMG 416 (velcalcetide), a novel peptide agonist of the calcium sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients","volume":"346","author":"Walter","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/ki.2013.289_bb0115","unstructured":"Martin KJ, Bell G, Pickthorn K et al. AMG 416, a novel peptide agonist of the calcium sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Submitted."},{"key":"10.1038\/ki.2013.289_bb0120","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","article-title":"Regulation of fibroblast growth factor-23 signaling by klotho","volume":"281","author":"Kurosu","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.289_bb0125","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"key":"10.1038\/ki.2013.289_bb0130","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2013.289_bb0135","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2215\/CJN.02640310","article-title":"Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u2018trade-off\u2019 hypothesis","volume":"5","author":"Gutierrez","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.289_bb0140","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2009.466","article-title":"FGF23-parathyroid interaction: implications in chronic kidney disease","volume":"77","author":"Komaba","year":"2010","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2013.289_bb0145","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"10.1038\/ki.2013.289_bb0150","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/ndt\/gfr384","article-title":"Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism","volume":"27","author":"Koizumi","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.289_bb0155","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1681\/ASN.2005111185","article-title":"Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D","volume":"17","author":"Liu","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.289_bb0160","doi-asserted-by":"crossref","first-page":"c94","DOI":"10.1159\/000086347","article-title":"Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism","volume":"101","author":"Nishi","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"10.1038\/ki.2013.289_bb0165","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2013.289_bb0170","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ndt\/gfn571","article-title":"Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2013.289_bb0175","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815561450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T04:57:28Z","timestamp":1596257848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815561450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0085253815561450"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.289","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}